Mark Lunt

Rates of serious infection, including site‐specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register

William G Dixon, K. Watson, Mark Lunt et al. · Arthritis & Rheumatism · 2006 · 752 citations

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)

William G Dixon, Kimme L Hyrich, Kath Watson et al. · Annals of the Rheumatic Diseases · 2009 · 701 citations · Full text

Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly

James Galloway, Kimme L Hyrich, Louise Mercer et al. · Lara D. Veeken · 2010 · 656 citations · Full text

Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti–tumor necrosis factor α therapy: Results from the British Society for Rheumatology Biologics Register

William G Dixon, Kath Watson, Mark Lunt et al. · Arthritis & Rheumatism · 2007 · 558 citations · Full text

Prevalence and Predictors of Intense, Chronic, and Disabling Neck and Back Pain in the UK General Population

Roger T. Webb, T. Brammah, Mark Lunt et al. · Spine · 2003 · 453 citations